The Company projects full year 2023 gross margin to be approximately 54%. This compares to previous guidance of approximately 53%. The Company projects full year 2023 total operating expense of approximately $167 million. This compares to previous guidance of approximately $163 million. The Company reiterates full year 2023 Adjusted EBITDA loss to be ($70.5) million.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRCT:
- PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
- Procept BioRobotics management to meet with B. Riley
- PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas
- Procept BioRobotics announces United Healthcare coverage of Aquablation therapy
- PROCEPT BioRobotics Corp. Announces Investor Event at 2023 AUA Annual Meeting in Chicago
